AU2003278497A8 - Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases - Google Patents

Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases

Info

Publication number
AU2003278497A8
AU2003278497A8 AU2003278497A AU2003278497A AU2003278497A8 AU 2003278497 A8 AU2003278497 A8 AU 2003278497A8 AU 2003278497 A AU2003278497 A AU 2003278497A AU 2003278497 A AU2003278497 A AU 2003278497A AU 2003278497 A8 AU2003278497 A8 AU 2003278497A8
Authority
AU
Australia
Prior art keywords
g3bp2
gtpase
ras
diagnostic
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003278497A
Other versions
AU2003278497A1 (en
Inventor
Heinz Von Der Kammer
Johannes Pohlner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec Neurosciences GmbH
Original Assignee
Evotec Neurosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences GmbH filed Critical Evotec Neurosciences GmbH
Publication of AU2003278497A8 publication Critical patent/AU2003278497A8/en
Publication of AU2003278497A1 publication Critical patent/AU2003278497A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
AU2003278497A 2002-06-20 2003-06-20 Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases Abandoned AU2003278497A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38992702P 2002-06-20 2002-06-20
EP02013692.5 2002-06-20
EP02013692 2002-06-20
US60/389,927 2002-06-20
PCT/EP2003/006521 WO2004001422A2 (en) 2002-06-20 2003-06-20 Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases

Publications (2)

Publication Number Publication Date
AU2003278497A8 true AU2003278497A8 (en) 2004-01-06
AU2003278497A1 AU2003278497A1 (en) 2004-01-06

Family

ID=56290442

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003278497A Abandoned AU2003278497A1 (en) 2002-06-20 2003-06-20 Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases

Country Status (3)

Country Link
EP (1) EP1514118A2 (en)
AU (1) AU2003278497A1 (en)
WO (1) WO2004001422A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
GB2419332A (en) 2004-10-22 2006-04-26 Gibbs Tech Ltd Steering arrangement with retractable wheels
BRPI0619249A2 (en) 2005-11-30 2011-09-20 Abbott Lab anti-globulin-ß antibodies, antigen-binding fractions thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of making said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
CN101506236B (en) 2005-11-30 2012-12-12 雅培制药有限公司 Monoclonal antibodies against amyloid beta protein and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
MX360403B (en) 2010-04-15 2018-10-31 Abbvie Inc Amyloid-beta binding proteins.
JP6147665B2 (en) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド Amyloid beta-binding protein
WO2023174838A1 (en) * 2022-03-14 2023-09-21 F. Hoffmann-La Roche Ag Modulators of the g3bp2-tau interaction for the treatment of tau associated diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780062B1 (en) * 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa MONOCLONAL ANTIBODIES DIRECTED AGAINST G3BP PROTEIN, AND USES THEREOF

Also Published As

Publication number Publication date
WO2004001422A3 (en) 2004-03-18
WO2004001422A2 (en) 2003-12-31
AU2003278497A1 (en) 2004-01-06
EP1514118A2 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
GB0418542D0 (en) Integrated biosensor and simulation system for diagnosis and therapy
EP1571970A3 (en) Diagnosis and monitoring of diseases
AU2002327792A1 (en) Diagnosis and treatment of diseases caused by mutations in cd72
IL153824A0 (en) Method and kit for diagnosis of diseases
AU2003253014A8 (en) Method for the diagnosis and differential diagnosis of neurological diseases
EP1572741A4 (en) Therapeutic and diagnostic agents
AU2003278497A8 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2003246380A1 (en) Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases
AU2003260301A8 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
AU2003279312A8 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
AU2002352054A1 (en) "in vitro" diagnostic method for diseases affecting human or animal tissues
AU2003250912A1 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
EP1539957A4 (en) Novel diagnostic and therapeutic methods and reagents therefor
AU2003288127A1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF H-Rev107 PROTEIN FOR ALZHEIMER DISEASE
AU2003294696A8 (en) Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases
AU2003265867A8 (en) A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
AU2003242588A8 (en) Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
AU2003222849A1 (en) Diagnostic and therapeutic use of ensadin-0255 gene and protein for neurodegenerative diseases
AU2003260460A1 (en) Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases
AU2003247252A1 (en) Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases
AU2003240746A8 (en) Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
AU2003209230A1 (en) Diagnosis and treatment for immunoglobulin e (ige) implicated disorders
AU2003263036A8 (en) Span-xb gene and protein for the diagnosis and treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase